Research programme: antibacterials - Microbiotix

Drug Profile

Research programme: antibacterials - Microbiotix

Alternative Names: 259C; AcrAB-TolC efflux pump inhibitors - Microbiotix; Aminospectinomycins - Microbiotix; AU-FQ hybrids; bIAI compounds; bis-imidazolinylindole compound series; Fatty acid biosynthesis (FAB) pathway inhibitors - Microbiotix; Inhibitors of DnaA initiator protein - Microbiotix; Inhibitors of initiation of DNA replication - Microbiotix; Inhibitors of wall teichoic acid (WTA) - Microbiotix; MBX 1158; MBX 1162; MBX 1196; MBX 1337; MBX 1339; MBX 1641; MBX 2319 analogues - Microbiotix; MBX 3132; MBX 3795; MBX 3796; MBX 3797; MBX 4191; MBX-500; Sortase A (SrtA) inhibitors for Gram-positive infections - Microbiotix; SOS induction inhibitors - Microbiotix; Spectinamide antibacterials for MDR/XDR tuberculosis - Microbiotix; Spectinomycin analogues - Microbiotix; T3SS inhibitors; TTSS inhibitors; Tuberculosis therapies - Microbiotix

Latest Information Update: 19 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Microbiotix
  • Developer GLSynthesis; Microbiotix
  • Class Acetamides; Amidines; Aminocyclitols; Carboxylic acids; Coumarins; Heterocyclic compounds; Imidazoles; Indoles; Pyrans; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA helicase inhibitors; DNA helicase-primase inhibitors; DNA synthesis inhibitors; DNA-binding protein inhibitors; DNA-directed DNA polymerase inhibitors; Lipoteichoic acid inhibitors; Membrane protein inhibitors; Sortase A inhibitors; Toll-like receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Gram-negative infections
  • No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections; Tuberculosis

Most Recent Events

  • 11 Jun 2018 Preclinical development development is ongoing in Bacterial infections in USA
  • 07 Jun 2018 Pharmacodynamics data from a preclinical studies in Gram-negative infections presented at the ASM Microbe 2018
  • 07 Jun 2018 Pharmacodynamics data from in vitro study presented at the ASM Microbe (ASMM-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top